Aclaris Therapeutics Inc (ACRS) stock forecast · rev $3.6M
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
This ACRS forecast page states what the cached financials imply — not a price target and not a guarantee. Aclaris Therapeutics Inc outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported ACRS revenue for 2026-06-30 was $3.6M. Net income was -$41.3M. Revenue was up 81.6% from 2026-03-31 to 2026-06-30. ACRS currently screens at market cap $615.9M.
The near-term path: Revenue was up 81.6% from 2026-03-31 to 2026-06-30. A forecast that ignores that change is just a story.
ACRS currently screens at market cap $615.9M. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next ACRS 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the ACRS stock page.
Not investment advice.